TG Therapeutics (TGTX) $8.09 is a small cap biotechnology company that focuses on the development of therapies for B-cell (blood) cancers and autoimmune diseases. One might initially think with these two different conditions, why would a company have such differentiated focuses? However, autoimmune diseases can be treated with the same or very similar agents to that which blood cancers are treated. A poster-child example would be CD-20 agents, such as rituximab. Ironically, one of TGTX’s lead candidates is a CD-20 targeting agent called ublituximab. Here, I will review TGTX’s current clinical pipeline, a . . .
About Chris Stang
As a young investor, I focus developing biotech companies. I focus strongly on fundamentals, digging deeper to understand the financial and regulatory position of companies. The biotechnology sector is very volatile, please use caution and do your own additional due diligence before investing. I also secondarily focus on small security and defense companies that provide long-term growth opportunities.